<unk>  is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe (known as Zetia in the United States) and the statin drug simvastatin (known as Zocor in the US). Ezetimibe reduces blood cholesterol by acting at the brush border of the small intestine and inhibiting the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzyme that is necessary for the body to make cholesterol. Generic versions were approved in 2017. The combination preparation is marketed by Merck & Co. under the trade names Vytorin in the US and Inegy in the European Union. In 2017, it was the 298th most commonly prescribed medication in the United States, with more than one million prescriptions.
Ezetimibe/simvastatin
Ezetimibe/atorvastatin
Bempedoic acid/ezetimibe
Ezetimibe/rosuvastatin
Fenofibrate/simvastatin
Fenofibrate/pravastatin
Amlodipine/atorvastatin
Sitagliptin/metformin